Status:
UNKNOWN
Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
GIS EPI-PHARE
Conditions:
AMD, ACEi's/ARB Prevent/Worsen Risk of COVID-19 Infection
Eligibility:
All Genders
18+ years
Brief Summary
The COVID-19 emerging disease due to a novel coronavirus (SARS-CoV-2), started in Wuhan, China, last December, 2019. In the past three months, the virus has spread rapidly worldwide to reach the pande...
Detailed Description
Details for "Study design" section Time perspective : Retrospective and prospective cohort study using French National Health Database Data source Enrollment: * 70,000 patients treated by synthetic...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All adults (18 years of age and older) registered in the French national health insurance database (SNDS) receiving between January 1, 2020, and May 31, 2020:
- Synthetic anti-malarial drugs (AMD): Participants will be identified by the prescription of at least one synthetic AMD (chloroquine and hydroxychloroquine, ATC P01D1 and M01C respectively)
- Anti-hypertensive drugs: Participants will be identified by the prescription of at least one Angiotensin receptor-blocking or Angiotensin converting- enzyme inhibitors, ATC C09A-D
- No Exclusion Criteria
Exclusion
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
6000000 Patients enrolled
Trial Details
Trial ID
NCT04356417
Start Date
April 1 2020
End Date
June 1 2020
Last Update
April 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hôpitaux de Paris - CHU Henri Mondor
Créteil, France, 94000